Skip to main content
    C

    CG Oncology, Inc. Common stock (CGON)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $84.78
    +10.38 (+13.95%)

    Market Cap: $6.65B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    CG Oncology, Inc. Common stock (CGON) Earnings: Report Dates and Results

    Updated Nov 6, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    CG Oncology, Inc. Common stock (CGON) is expected to report earnings on Feb 25, 2027. In the quarter ended Sep 30, 2026, CG Oncology, Inc. Common stock reported EPS of -$0.64, above the -$0.86 estimate. It beat the EPS estimate in 1 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    33%(4/12)
    Avg Surprise
    -12.26%
    Streak
    1 Q

    Upcoming Estimates

    Reports Feb 25, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.84
    Range-$1.01 - -$0.62
    16 analysts
    Revenue Consensus
    $644.30K
    RangeN/A
    14 analysts
    Reports May 6, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.74
    Range-$0.80 - -$0.66
    3 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.89+17.2%
    60d ago-$0.89+17.2%
    30d ago-$0.89+17.2%
    7d ago-$0.89+17.2%
    Current-$0.74
    Revenue Consensus
    $400.00K
    RangeN/A
    4 analysts

    Next Report

    CGON has an expected report date of Feb 25, 2027.

    Earnings History

    Of the 12 quarters below that had an estimate, CGON beat 4 and missed 8. Revenue for the quarter ended Sep 30, 2026 was $1.60M, down 4.2% from $1.67M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.64-$0.86-$0.96 - -$0.66+25.58%BeatN/A120 up, 10 downNov 6, 2026$1.60M
    Jun 30, 2026-$0.90-$0.70-$0.73 - -$0.52-28.57%MissN/A113 up, 6 downAug 6, 2026$1.16M
    Mar 31, 2026-$0.71-$0.58-$0.66 - -$0.43-22.41%MissN/A105 up, 0 downMay 8, 2026$1.08M
    Dec 31, 2025-$0.51-$0.48N/A-6.25%MissN/A122 up, 5 downFeb 27, 2026$2.32M
    Sep 30, 2025-$0.57-$0.55-$0.63 - -$0.48-3.64%MissN/A100 up, 1 downNov 14, 2025$1.67M
    Jun 30, 2025-$0.54-$0.45-$0.50 - -$0.37-20.00%MissN/A82 up, 1 downAug 8, 2025N/A
    Mar 31, 2025-$0.45-$0.37-$0.51 - -$0.13-21.62%MissN/A5N/AMay 13, 2025$52000
    Dec 31, 2024-$0.46-$0.45N/A-2.22%MissN/A11 up, 1 downMar 28, 2025$567000
    Sep 30, 2024-$0.30-$0.34-$0.57 - -$0.28+11.76%BeatN/A51 up, 0 downNov 14, 2024$43000
    Jun 30, 2024-$0.28-$0.31-$0.53 - -$0.23+9.68%BeatN/A51 up, 0 downAug 8, 2024N/A
    Mar 31, 2024-$0.36-$0.15N/A-140.00%MissN/AN/AN/AMay 9, 2024$529000
    Dec 31, 2023-$0.33-$0.67N/A+50.61%BeatN/AN/AN/AMar 26, 2024$1000
    Last 12 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$2.07, after -$1.40 the year before. It was -$0.33 for the year ended Dec 31, 2023, the oldest of the 3 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$2.07N/A
    Dec 31, 2024-$1.40N/A
    Dec 31, 2023-$0.33N/A

    Frequently Asked Questions About CGON

    When is CG Oncology, Inc. Common stock's next earnings date?

    CG Oncology, Inc. Common stock's next earnings report is expected for Feb 25, 2027.

    Did CGON beat earnings estimates last quarter?

    Yes. CG Oncology, Inc. Common stock reported EPS of -$0.64 for the quarter ended Sep 30, 2026, above the -$0.86 estimate, a 25.58% surprise.

    What EPS do analysts expect from CGON next quarter?

    The consensus EPS estimate for CG Oncology, Inc. Common stock for the quarter ending Dec 31, 2026 is -$0.84 from 16 analysts, with estimates from -$1.01 to -$0.62.

    How often does CGON beat earnings estimates?

    CG Oncology, Inc. Common stock beat the EPS estimate in 1 of the last 8 quarters, with an average surprise of -9.89%.